Remon, J., Esteller, L., & Taus, Á. (2019). Nivolumab plus ipilimumab combination therapy for the first-line treatment NSCLC: Evidence to date. Cancer Manag Res.
Stile di citazione ChicagoRemon, Jordi, Laura Esteller, e Álvaro Taus. "Nivolumab Plus Ipilimumab Combination Therapy for the First-line Treatment NSCLC: Evidence to Date." Cancer Manag Res 2019.
Citazione MLARemon, Jordi, Laura Esteller, e Álvaro Taus. "Nivolumab Plus Ipilimumab Combination Therapy for the First-line Treatment NSCLC: Evidence to Date." Cancer Manag Res 2019.
Attenzione: Queste citazioni potrebbero non essere precise al 100%.